Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD
NCT06431256
Recruiting
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Gender:
ALL
Ages:
Between 4 years and 5 years
Trial Updated:
03/14/2025
Locations: HLD200-112 Study Site, Dothan, Alabama
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates
Investigating Inhibitory Control Networks in Parkinson's Disease
NCT04735458
Recruiting
The purpose of this study is to investigate the brain activity associated with non-motor symptoms of movement disorders, including Parkinson's disease and essential tremor. These movement disorders commonly have significant non-motor features also, including depression, cognitive impairment, decreased attention, and slower processing speeds. The investigators are interested in the brain activity associated with these symptoms, and perform recordings of the surface of the brain, in addition to th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Veterans Administration Medical Center - Birmingham, Birmingham, Alabama
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840635, Andalusia, Alabama
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Retraining and Control Therapy (ReACT) R33 Phase
NCT06007053
Recruiting
The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of pediatric psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 11-18-year-olds diagnosed with PNES will engage in twelve sessions of either ReACT or supportive therapy. Sense of control over actions w... Read More
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
03/10/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Convulsion, Non-Epileptic
Register for Updates
A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures
NCT05819268
Recruiting
The purpose of this study is to assess the feasibility of conducting a future fully powered multi-site efficacy Randomized Controlled Trial (RCT) comparing two treatments for pediatric functional seizures (FS). In this study, 11-18-year-olds diagnosed with FS will be randomized to 12 sessions of Retraining and Control Therapy (ReACT) or Competent Adulthood Transition with Cognitive Behavioral, Humanistic, and Interpersonal Training (CATCH-IT) at 3 sites: University of Alabama at Birmingham, Yale... Read More
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
03/10/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Functional Seizures, Convulsion, Non-Epileptic
Register for Updates
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT04606914
Recruiting
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eli... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of Alabama at Birmingham Womens & Infants Center, Birmingham, Alabama
Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Trinity Clinical Research, LLC, Bessemer, Alabama
Conditions: SARS-CoV-2
Register for Updates
Effect of Preoperative Mobility Device Training on Postoperative Fall Incidence
NCT03857945
Recruiting
The purpose of this study is to determine whether preoperative mobility device training is beneficial in reducing incidence of postoperative falls in patients undergoing elective foot and ankle surgery requiring a postoperative period of no weight-bearing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: UAB Hospital Highlands, Birmingham, Alabama
Conditions: Injury; Muscle, Ankle, and Foot, Multiple
Register for Updates
Comparison of Procedural Sedation in TEE
NCT06129188
Recruiting
The objective of this proposal is to conduct a prospective randomized study comparing the utility of sedating patients undergoing transesophageal echocardiographic studies with a novel, recently-FDA-approved sedative agent, remimazolam, versus the sedative used in our current practice at UAB, propofol. This study will investigate whether remimazolam offers any benefit over current care vis-à-vis hemodynamics or efficiency/throughput. This study will be conducted at the University of Alabama at... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/06/2025
Locations: University of Alabama at Birmingham Hospital, Birmingham, Alabama
Conditions: Anesthesia
Register for Updates
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
NCT06033950
Recruiting
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: FIN-10004 Fairhope, AL Investigational Site, Fairhope, Alabama
Conditions: Heart Failure
Register for Updates
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT06024746
Recruiting
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: CON-10004 Fairhope, AL Investigational Site, Fairhope, Alabama
Conditions: Heart Failure
Register for Updates